In a joint statement Danish drugmaker Novo Nordisk and U.S. drug developer Prothena Corp said, the former will acquire the latter’s experimental heart therapy PRX004, in a deal that could be worth up to $1.23 billion. Novo’s acquisition is in… Read More ›